



**Public Disclosure on Liquidity Risk as required by RBI circular DOR.NBFC (PD) CC. No.102/03.10.001/2019-20 dated 04 November 2019 for Clix Capital Services Pvt Ltd as of Dec 31, 2021**

(i) **Funding Concentration based on significant counterparty (both deposits and borrowings):**

Number of Significant Counterparties*	Amount* (INR Cr)	% of Total Deposits	% of Total Liabilities
18	1,827	NA	75%

\* Total Borrowings represents Total Borrowings reduced by liability against Securitized Portfolio

(ii) **Top 20 large deposits (amount and % of total deposits):**

Not Applicable.

(iii) **Total of top 10 borrowings (amount and % of total borrowings):**

Amount (INR Cr)	% of Total Borrowings*
1,497	73%

\*Total Borrowings represents Total Borrowings reduced by liability against Securitized Portfolio

(iv) **Funding Concentration based on significant instrument / product:**

Sr. No.	Name of the instrument/product	Amount (INR Cr)	% of Total Liabilities
1	Non-Convertible Debentures	760	31%
2	Bank Borrowings	740	31%
3	Term Loan from others	478	20%
4	Commercial papers	71	3%

(v) **Stock Ratios:**

Sr. No.	Particulars	% of Total Public Funds	% of Total Liabilities	% of Total Assets
1	Commercial papers	3%	3%	2%
2	Non-convertible debentures (original maturity of less than one year)	-	-	-
3	Other short-term liabilities#	50%	47%	27%

# Other Short Term Liabilities includes debt securities embedded with options due within one year.

(vi) **Institutional set-up for liquidity risk management:**

The Board of Directors has the overall responsibility for establishing the risk management framework for the Company. The Board, in turn has established an ALM Committee (ALCO) for evaluating, monitoring, and reviewing liquidity and interest rate risk arising in the Company on both sides of the Balance sheet. The Board based on recommendations from the ALCO has prescribed policies and the risk limits for the management of liquidity risk. ALCO committee is responsible for managing the risks arising out of Asset Liability mismatches consistent with the regulatory requirements and internal risk tolerances established by the Board. Amongst other responsibilities, ALCO has been empowered to decide the funding mix for the Company in light of the future business strategy and prevailing market conditions. ALCO committee is conducted at least once in a quarter and the ALCO minutes are reviewed by the Board from time to time.

Note: The amount stated in this disclosure is based on the provisional financial statements for the quarter ended Dec 31, 2021.